Celanese Corporation (NYSE: CE), an international company specializing in specialty materials and chemicals, and Secarna Pharmaceuticals GmbH & Co. KG, a leading independent European company in the discovery and development of antisense oligonucleotide (ASO) therapeutics, have announced a collaboration in research and development of sustained-release implants delivering ASOs.
Innovative ASO Therapy
ASOs are synthetic molecules designed to target specific RNA, preventing the production of proteins involved in a wide range of diseases, including cardiometabolic, central nervous system, oncological, and rare diseases. While ASO therapy is an innovative and commercially viable therapeutic approach, it often requires frequent administration or high doses to achieve the desired effect, imposing a significant burden on patients.
Don’t miss out on market opportunities. With ProfitsForce, you’ll have access to valuable insights and data to guide your investment decisions. Subscribe now and stay ahead of the curve!
Platform Collaboration for Enhanced Delivery
Celanese’s drug delivery platform, VitalDose®, and Secarna’s patented ASO discovery and development platform will be utilized to develop implants containing ASO eluates. These implants aim to reduce administration frequency, minimize off-target immune responses, and enhance targeting to deliver better patient outcomes across various indications. VitalDose® drug delivery platform ensures reliable controlled release and has a proven track record in approved parenteral drugs in the United States and Europe. It can be tailored to provide drug release from several months to several years and has demonstrated stable ASO release over one year.
Transforming ASO Treatment Methods
The collaboration with Secarna enables Celanese to develop an innovative implant that has the potential to significantly alter ASO treatment methods, modifying the course of the disease. By leveraging the expertise and technologies of both companies, this partnership aims to revolutionize ASO therapy, offering patients more effective and convenient treatment options.
Empower Your Investment Strategy with ProfitsForce
Interested in staying ahead of innovative partnerships like Celanese and Secarna’s collaboration? Explore ProfitsForce, our comprehensive investment platform, to analyze market trends and make informed investment decisions. Unlock the potential of the pharmaceutical industry with ProfitsForce.
Top 3 Dividend Stocks for Reliable Income
Top Stocks with Remarkable Growth in 2024
